Intervention not reported
Overall survival ‐ trials of metastatic breast cancer participants unselected for TNBC · women with metastatic breast cancer unselected for triple‐negative breast cancer (TNBC)
The intervention showed no clear difference in overall survival ‐ trials of metastatic breast cancer participants… (high certainty).
1 finding from 1 review
Intervention not reported
Leukopenia** grade 3 or 4 (safety population) · women with metastatic breast cancer
The intervention probably leads to higher leukopenia** grade 3 or 4 (safety population) (moderate certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival/time to progression (randomised participants) ‐ trials of metastatic breast cancer participants unselected for TNBC · women with metastatic breast cancer unselected for triple‐negative breast cancer (TNBC)
The intervention showed no clear difference in progression‐free survival/time to progression (randomised… (moderate certainty).
1 finding from 1 review
Intervention not reported
Objective tumour response rate (assessable participants) ‐ trials of metastatic breast cancer participants unselected for TNBC · women with metastatic breast cancer unselected for triple‐negative breast cancer (TNBC)
The intervention may leads to higher objective tumour response rate (assessable participants) ‐ trials of… (low certainty).
1 finding from 1 review
Intervention not reported
Overall survival ‐ trials of mTNBC participants · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention showed no clear difference in overall survival ‐ trials of mTNBC participants (low certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival/time to progression (randomised participants) ‐ trials of mTNBC participants · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to lower progression‐free survival/time to progression (randomised… (low certainty).
1 finding from 1 review
Intervention not reported
Objective tumour response rate (assessable participants) ‐ trials of mTNBC participants · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to higher objective tumour response rate (assessable participants) ‐ trials of… (low certainty).
1 finding from 1 review
Intervention not reported
Nausea/vomiting* grade 3 or 4 (safety population) by type of platinum agent in platinum regimen · women with metastatic breast cancer
The intervention probably leads to lower nausea/vomiting* grade 3 or 4 (safety population) by type of… (moderate certainty).
1 finding from 1 review
Intervention not reported
Anaemia grade 3 or 4 (safety population) by type of platinum agent in platinum regimen · women with metastatic breast cancer
The intervention leads to higher anaemia grade 3 or 4 (safety population) by type of platinum agent… (high certainty).
1 finding from 1 review
Intervention not reported
Hair loss grade 3 or 4 (safety population) · women with metastatic breast cancer
The intervention leads to higher hair loss grade 3 or 4 (safety population) (high certainty).
1 finding from 1 review
Bone metastases · women with early breast cancer
Bisphosphonates probably leads to lower bone metastases compared with placebo/observation (moderate certainty).
1 finding from 1 review
Infusion‐related events · women with early breast cancer
1 finding from 1 review
Bone metastases · women with advanced breast cancer without bone metastases
Bisphosphonates showed no clear difference in bone metastases compared with placebo/observation (moderate certainty).
1 finding from 1 review
Median time to a skeletal‐related event · women with advanced breast cancer without bone metastases
1 finding from 1 review
Overall survival · women with advanced breast cancer without bone metastases
Bisphosphonates showed no clear difference in overall survival compared with placebo/observation (high certainty).
1 finding from 1 review
Quality of life · women with advanced breast cancer without bone metastases
1 finding from 1 review
Skeletal‐related event (SRE) · women with metastatic breast cancer with bone metastases
Bisphosphonates leads to lower skeletal‐related event (SRE) compared with placebo/observation (high certainty).
1 finding from 1 review
Median time to a skeletal‐related event · women with metastatic breast cancer with bone metastases
1 finding from 1 review
Overall survival · women with metastatic breast cancer with bone metastases
Bisphosphonates showed no clear difference in overall survival compared with placebo/observation (moderate certainty).
1 finding from 1 review
Bone pain · women with metastatic breast cancer with bone metastases
1 finding from 1 review